Prudential Financial Inc Lineage Cell Therapeutics, Inc. Transaction History

Prudential Financial Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.12 - $1.61 $11,743 - $16,880	-10,485 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.84 - $2.68 $1,499 - $2,184	-815 Reduced 7.21%	10,485 $26,000
Q3 2021 Nov 15, 2021	SELL	$2.26 - $2.86 $18,979 - $24,018	-8,398 Reduced 42.63%	11,300 $28,000
Q4 2019 Feb 11, 2020	BUY	$0.54 - $1.01 $1,277 - $2,389	2,366 Added 13.65%	19,698 $17,000
Q3 2019 Nov 13, 2019	BUY	$0.85 - $1.24 $14,732 - $21,491	17,332 New	17,332 $16,000

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $84.9M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.